Understand the source comparison
Best SS-31 for Cardioprotection: Quality Comparison
Choosing SS-31 for cardiac research requires evaluating purity, documentation, and structural verification across suppliers. The table below compares key quality markers. Pharmaceutical-grade (Real Peptides) ≥98% with CoA LC-MS/MS per batch ≤5 EU/mg verified D
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Choosing SS-31 for cardiac research requires evaluating purity, documentation, and structural verification across suppliers. The table below compares key quality markers.
- Pharmaceutical-grade (Real Peptides)
- ≥98% with CoA
- LC-MS/MS per batch
- ≤5 EU/mg verified
- Documented degradation profile at 2–8°C
- Required standard for cardioprotection research—structural fidelity and endotoxin control are non-negotiable for mitochondrial targeting
- Research-grade (mid-tier suppliers)
- 95–98% claimed
- HPLC only, no mass spec
- Not routinely tested
- General guidance only
- Suitable for preliminary screening but lacks verification to confirm exact tetrapeptide sequence
- Bulk peptide vendors
- 90–95% typical
- Not provided
- Not tested
- Not documented
- High risk of deletion sequences or racemization—unpredictable cardiolipin binding and confounded results
- Compounded preparations
- Variable, often undocumented
- Rarely verified
- Inconsistent
- Unknown
- Not recommended for controlled studies where mitochondrial mechanism must be isolated
- Real Peptides synthesizes SS-31 Elamipretide in small batches with LC-MS/MS confirmation of the D-Arg-Dmt-Lys-Phe-NH2 sequence and ≤5 EU/mg endotoxin levels documented on every CoA. This level of verification is what published cardioprotection studies use—it's the baseline, not a premium feature.